Design Therapeutics (DSGN)
(Delayed Data from NSDQ)
$4.90 USD
+0.12 (2.51%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $4.91 +0.01 (0.20%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
DSGN 4.90 +0.12(2.51%)
Will DSGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DSGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DSGN
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
DSGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DSGN
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Larimar stock rallies 24% on FDA removal of partial clinical hold
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review